Funding
Opportunities are assessed in a rigorous process. Investments include seed, Series A, and later-round funding for startups.
OUR APPROACH
Pandect Bioventures identifies transformational healthcare ideas at
the earliest stage, then leverages the knowledge and resources of our rich ecosystem to help build these ideas into successful life science companies.
Incubator
Access to a 40,000 square foot incubator facility provides fertile ground for growing and cultivating investment opportunities.
Expertise
Top academic and industry advisors bring experience from every stage of company formation and growth, from management teams to identifying disease targets.
Collaborators
Exclusive relationships with research institutions provide unique access to emerging discoveries, top advisors, intellectual property and research infrastructure.
Customized support to grow your idea into a well-funded company
Management
Our management and executives-in-residence bring decades of experience to our investment picks and portfolio growth.
Executives in Residence and Strategic Advisors
Founding Executives in Residence
David Spellmeyer, Ph.D.
Krishna Kodukula, Ph.D.
Robert Wild, Ph.D.
Robert Lutz, Ph.D.
FOR ENTREPRENEURS
Embracing a founder-centric approach, Pandect Bioventures works closely with scientific innovators to advance discoveries rapidly through key value-inflection points.
We review hundreds of investment opportunities per year — each one vetted by a team of principals and executives-in-residence. If merited, opportunities advance through a more detailed due diligence process with subject-area experts.
MORE RESOURCES
PORTFOLIO
Circle Pharma
In 1Q 2020, we co-invested with The Column Group and Nextech Invest in Circle’s Series B. Circle Pharma is developing a new paradigm for cell permeable macrocyclic peptide discovery based on rational design and synthetic chemistry. The Chair of Circle’s SAB, William G. Kaelin Jr. MD (Harvard Medical School/Dana Farber Cancer Institute), received a Nobel Prize in Medicine and Physiology in 2019. For more information, see: www.circlepharma.com.
Year Invested
2020
Therapeutic Area
Oncology
Area of Focus
Macrocycles
Status
Private
Location
South San Francisco, CA
Website
circlepharma
Azkarra Therapeutics
In 2019, we formed an oncology newco at the ShangPharma incubator with a UCSF co-founder, Alan Ashworth PhD/FRS (President of the UCSF Helen Diller Family Comprehensive Cancer Center and Senior Vice President for Cancer Services with UCSF Health), and led the Seed round in 2Q 2020. Azkarra’s mission is to deliver new oncology therapies to patients based on the team’s deep expertise in DNA Damage Response (DDR). For more information, see: www.azkarrabio.com.
Year Invested
2019
Therapeutic Area
Oncology
Area of Focus
DNA Damage Response
Status
Private
Location
South San Francisco, CA
Website
azkarrabio
Valitor
In 2019, we co-led Valitor’s Series A with Berkeley Catalyst Fund. Valitor is a biotech spin-out from the University of California, Berkeley (College of Chemistry and Bioengineering Professors Kevin Healy PhD and David Schaffer PhD, both serial entrepreneurs). Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. For more information, see: www.valitorbio.com.
Year Invested
2019
Therapeutic Area
Ophthalmology
Area of Focus
Multi-Valent Protein Conjugates
Status
Private
Location
Berkeley, CA
Website
valitorbio
Walking Fish Therapeutics
In Q3 2021, we co-invested with The Emerson Collective in Walking Fish Therapeutics’ Series A. WFTx is a leader in B cell medicines, and has made critical advances in engineering technologies to rapidly advance cell-based therapeutics to treat serious diseases, concentrating on oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. For more information and important updates, please visit https://www/pandectbio_129/public.walkingfishtx.com/
Year Invested
2021
Therapeutic Area
Oncology
Area of Focus
Cell Based Therapeutics
Status
Private
Location
South San Francisco
Website
www.walkingfishtx.com
Walden Biosciences
In 1Q 2020, we co-invested with Arch Venture Partners in Walden’s Series A. Walden is applying a dynamic, systems-based approach to understand kidney disease and develop breakthrough medicines for both rare and prevalent forms of the disease. This entails utilizing interconnected approaches to study and validate targets and produce medicines directed to the kidney. For more information, see: www.waldenbiosciences.com
Year Invested
2020
Therapeutic Area
Nephrology
Area of Focus
Kidney Disease
Status
Private
Location
Cambridge, MA
Website
www.waldenbiosciences.com
